BioSpace News Archive

Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the gastro intestine that includes ulcerative colitis and Crohn’s disease.

There’s been a surge in demand for complete NASH therapeutics in the past couple of years, which in turn has led to the projected launch of pipeline drugs.

Osteoarthritis is one of the most draining diseases and so far, no therapy can effectively treat structural deterioration of bones and cartilage or any course of medicine to reverse any existing structural defects.

As per Precedence Research, the healthcare informatics market size is expanding at US$ 84.4 billion by 2029 and expected to registered growth at a CAGR of 12.2% from 2021 to 2030.

Median Technologies (ALMDT:PA) (Paris:ALMDT) announces today that the company will publish its 2021 annual results on April 21, 2022 after trading.

Phantom Neuro, a burgeoning neurotechnology startup that delivers a low power, high accuracy system for lifelike control of robotic orthopedic technologies, today announced a $3.26 million funding round from leading international and U.S.-based investors.

Advanced Dermatology and Cosmetic Surgery announces that, board-certified dermatologist Mark Kaufmann, MD, FAAD, begins his one-year term as president of the American Academy of Dermatology at the conclusion of the 2022 AAD Annual Meeting in Boston.

sanofi-aventis Canada Inc. announced the approval of Libtayo® for the treatment of adult patients with cervical cancer who have progressed on or after prior platinum-based chemotherapy and who require additional systemic therapy to treat recurrent or metastatic disease.

SQI Diagnostics Inc. announced today that Company CEO Andrew Morris has been invited to present at the 2022 Virtual Growth Conference.

Fluidigm Corporation (NASDAQ:FLDM) today announced that it convened and then adjourned, without conducting any other business, the Company’s Special Meeting of Stockholders (the “Special Meeting”) to provide stockholders additional time to vote on the previously announced strategic capital infusion from leading life sciences investors Casdin Capital, LLC (“Casdin”) and Viking Global Investors LP (“Viking”).